XML 18 R42.htm IDEA: XBRL DOCUMENT v3.2.0.727
Segment Information and Concentration of Business Risk (Details)
$ in Thousands
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2015
USD ($)
Jun. 30, 2014
USD ($)
Jun. 30, 2015
USD ($)
Segment
Partner
Jun. 30, 2014
USD ($)
Dec. 31, 2014
Partner
Segment Information and Concentration of Business Risk [Abstract]          
Number of reportable segments | Segment     2    
Revenues [Abstract]          
Research and development revenue $ 119,658 $ 56,628 $ 181,551 $ 76,177  
Licensing and royalty 770 448 1,461 9,060  
Total revenue 120,428 57,076 183,012 85,237  
Income (loss) from operations 44,646 (6,650) 35,317 (36,317)  
Operating Segments [Member] | Isis Core [Member]          
Revenues [Abstract]          
Research and development revenue 119,658 56,628 181,551 76,177  
Licensing and royalty 770 448 1,461 9,060  
Total revenue 120,428 57,076 183,012 85,237  
Income (loss) from operations 53,588 (1,042) 51,357 (26,653)  
Operating Segments [Member] | Akcea Therapeutics [Member]          
Revenues [Abstract]          
Research and development revenue 0 0 0 0  
Licensing and royalty 0 0 0 0  
Total revenue 0 0 0 0  
Income (loss) from operations $ (8,942) $ (5,608) $ (16,040) $ (9,664)  
Revenue [Member] | Partner A [Member]          
Significant Partners [Abstract]          
Concentration percentage 76.00% 0.00% 50.00% 0.00%  
Revenue [Member] | Partner B [Member]          
Significant Partners [Abstract]          
Concentration percentage 15.00% 60.00% 31.00% 52.00%  
Revenue [Member] | Partner C [Member]          
Significant Partners [Abstract]          
Concentration percentage 4.00% 6.00% 11.00% 8.00%  
Revenue [Member] | Partner D [Member]          
Significant Partners [Abstract]          
Concentration percentage 1.00% 27.00% 1.00% 22.00%  
Contracts Receivable [Member] | Significant Partners [Member]          
Significant Partners [Abstract]          
Concentration percentage     100.00%   99.00%
Number of significant partners | Partner     3   3